The company has increased its testing capacity to over 1 lakh annual tests, with the installation of the latest Illumina NovaSeq 6000 DNA sequencing platform
Clevergene Biocorp, a Bangalore based genomics company has increased its testing capacity to over 1 lakh annual tests, with the installation of the latest Illumina NovaSeq 6000 DNA sequencing platform.
The added capacity will open new horizons for highly powered experiments at the depth required to discover rare genetic events. With this addition, Clevergene will be able to explore new horizons to widen its discovery genomics offerings by introducing applications such as single cell gene expression, genome deep sequencing etc, that requires large volumes of DNA sequence data. Clevergene is also aiming at leading genetic diagnostics with a focus to provide diagnosis for rare and difficult to diagnose genetic ailments.
Speaking on this latest addition Tony Jose, Co-Founder & CEO of Clevergene said, “Our primary intention behind this investment is to scale up our genetic diagnostics portfolio and make available comprehensive genetic diagnosis to the millions of patients suffering with genetic ailments. We are also expanding our discovery genomics offerings to Europe and North America.”
The addition of this critical piece of infrastructure is great news for top life science research institutions, speciality hospitals and diagnostics companies who have been looking for a partner in Genomics with capabilities in high-throughput sequencing and deep tech genome analysis.